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Summary.-Antigens associated with cells transformed in vivo by FBJ virus, a
wild type murine sarcoma virus (MSV) complex originating from a spontaneously
arising osteosarcoma in a CF1 mouse, have been partially characterized by comple-
ment fixation (CF). Using rat antisera against antigens specified by Gross leukaemia
virus (GLV) the group specific (gs) antigen of C-type RNA murine tumour viruses
was demonstrated in FBJ tumours as well as in GLV rat leukaemias, AKR lympho-
mata and sarcomata induced by MSV-H (Harvey), an MSVisolateofFriend-Moloney-
Rauscher (FMR) subgroup specificity. Using mouse antisera against antigens
present in FBJ cells the Gross (G) or wild type specificity of FBJ tumours
was demonstrated by cross reactivity with antigens expressed on normal AKR
lymphoid tissues and leukaemias. These antigens were absent from MSV-H
induced sarcomata and in reciprocal tests mouse antisera to MSV-H failed to react
with antigens present in FBJ tumour cells. No distinction between cellular and
virion antigens expressed by FBJ cells was possible by CF although evidence for a
cellular antigen with G specificity was obtained in tests using aged C57B1 antiserum
containing a naturally occurring G antibody lacking significant virus neutralizing
capacity. However, the likelihood that mouse FBJ antisera contain antibodies to
type specific viral envelope antigens (VEA) as well as cellular antigen is discussed.
FBJ OSTEOSARCOMA virus, isolated
originally from- a spontaneously arising
osteosarcoma in a CF1 mouse (Finkel,
Biskis and Jinkins, 1966) is unique among
strains of murine sarcoma virus (MSV)
in producing only sarcomata in mice
(Yumoto et al., 1970; Price, Moore and
Jones, 1972). This virus (MSV-FBJ)
and the non-pathogenic virus (MLV-FBJ)
with which it is associated (Levy et at.,
1973) are similar to members of the RNA
murine leukaemia-sarcoma virus complex
with respect to morphology, density
and biological activity in tissue culture
(Kelloff et al., 1969; Rhim et al., 1969).
In a previous paper it was shown
that in vivo transformed cells releasing
MSV-FBJ and MLV-FBJ possess cell
surface antigens capable of inducing
transplantation resistance in syngeneic
hosts (Jones and Moore, 1973). In
parallel studies, the antigenic relation-
ship of FBJ sarcomata to murine neo-
plasms of Gross (G) or "wild " type
specificity and another MSV isolate,
MSV-H (Harvey, 1964) of Friend-
Moloney-Rauscher (FMR) subgroup speci-
ficity (Harvey and East, 1971) has been
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investigated. Two serological procedures
have been employed for antigenic defini-
tion of these virus induced neoplasms,
viz. complement fixation (CF) and indirect
membrane immunofluorescence (MIF).
Data obtained by the former technique
are presented in this paper.
MATERIALS AND METHODS
Animrals.-All animals employed in this
study were bred and maintained in our
colony by strict brother-sister mating and
were tested periodically for genetic uniformity
by skin grafting. These included AKR,
C57B1 and CBA(H) mouse strains and rats
of the AS Wistar strain. Particular care
was taken to segregate mice infected with
Gross, MSV-FBJ and MSV-H viruses
respectively.
Tumours.-FBJ sarcomata induced by
neonatal injection of MSV-FBJ (Jones and
Moore, 1973), were transplanted in syngeneic
CBA(H) mice and used within 10 generations
of in vivo passage. Spleens were taken from
mice bearing primary FBJ tumours.
Gross (G) antigen positive tissues were
obtained from primary leukaemic and pre-
leukaemic AKR mice and from AS rats
which developed lymphomata following neo-
natal injection of a 10-1 dilution of Rat
Adapted Gross Passage A virus (Batch-VR
589 2 D, American Type Culture Collection,
Rockville, Maryland, U.S.A.). Rat lympho-
mata were transplanted in syngeneic reci-
pients by subcutaneous implantation of
tumour brie.
MSV-H induced sarcomata developed in
syngeneic CBA(H) mice following neonatal
injection into the thigh muscle of cell free
preparations of MSV-H generously supplied
by Dr J. J. Harvey (MRC Clinical Research
Centre, Northwick Park, Harrow, Middlesex).
Primary sarcomata were passaged in CBA(H)
mice which had received 400 rad whole body
x-irradiation, as subcutaneous implants or
minced finely in Eagle's Minimal Essential
Medium (Eagle's MEM Biocult Labora-
tories, Paisley, Scotland) and the resultant
brie filtered through sterilized wire cloth into
autoclaved centrifuge tubes. After washing
twice at 600 rev/min (80 g) in fresh Eagle's
MEM, cells were seeded into Falcon plastic
tissue culture flasks at 2 x 105 cells/ml in
Eagle's MEM containing 10% foetal bovine
serum. Monolayers were subcultured when
they approached confluence and subsequent
passages -ere harvested for antigen
preparation.
Leukaemias induced in RF mouse strains
(HI and OR) by x-irradiation were obtained
from Dr A. W. Craig, Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester.
A transplantable leukaemia (AF) of
spontaneous origin in a female A strain
mouse was supplied to us by Dr J. Marchant
(Department of Cancer Studies, University
of Birmingham), and radiation induced
transplanted murine osteosarcomata (Moore
and Williams, 1972) by Dr J. Loutit,
(MRC Radiobiology Unit, Harwell, Dideot,
Berkshire).
Sera. Heterologous antisera-Rat anti-
sera directed against antigens of the murine
leukaemia/sarcoma virus complex were
obtained from two sources: (a) Wistar rats
carrying transplants of AKR virus induced
lymphomata; this serum was supplied by the
Programmed Resources Division, Special
Virus Programme, National Cancer Institute,
Bethesda, Maryland, U.S.A. It was un-
reactive at a dilution of 1: 20 or greater with
a variety of normal tissues and also tissues
infected with possible contaminant DNA
viruses; (b) from AS rats in our laboratory
bearing first generation transplants of Gross
Passage A virus induced lymphomata.
Homologous sera-Serum was obtained asep-
tically from the retro-orbital sinus 10 days
after mice had been immunized either by
bilateral implantation of irradiated isografts
of tumour tissue or following excision of a
growing subcutaneous FBJ sarcoma nodule
(Jones and Moore, 1973).
Antisera to FBJ tumours were pro-
duced in syngeneic CBA(H) mice by a
minimum of 4 intraperitoneal injections of
x-irradiated (15,000 rad) sarcoma cells at a
minimum cell dose of 2 x 106 cells/animal.
MSV-H antisera were produced by injec-
tion of oncogenic cell free preparations of
MSV-Harvey into the peritoneal cavity of
syngeneic CBA(H) mice.
C57B1 antisera to Gross (G) cell surface
antigens were obtained by exsanguination of
individual aged female C57B1 mice (Aoki,
Boyse and Old, 1966). Only sera which
were reactive in the indirect membrane
immunofluorescence test with FBJ sarcoma
cells or Gross virus induced leukaemia
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cells (Jones and Moore, to be published)
were used in complement fixation tests.
Control sera were obtained from untreated
young male CBA(H) and congenic CBAT6T6
mice or AS rats and from CBA(H) mice
immunized by repeated irradiated isograftinig
with syngeneic radiation induced murine
sarcomata of putatively non-viral origin.
Antigens.-Crude antigen extracts were
prepared at 4°C from either fresh homo-
genates of malignant, virus infected non-
malignant and normal tissues or tissue
culture cell packs, by the following method:
A 20% (w/v) suspension of tumour was
prepared in phosphate buffered saline and
ground to an even consistency in a mortar
and pestle. Tissue culture cells were de-
tached from culture flasks by scraping with
a rubber policeman, packed by centrifugation
at 600 g in a graduated centrifuge tube and
a 20% (v/v) suspension prepared.
Antigen extracts were then rapidly frozen
to -197°C, slowly thawed 3 times and finally
sonicated for 30 sec/ml material using an
MSE sonicator (MSE Ltd., Crawley, Sussex)
with a 1 cm titanium probe at a wavelength
of 7 jtm peak to peak.
Crude antigen extracts were thereafter
spun at 200 g for 5 min to remove large
particulate material and diluted 1: 4 with
proprietary complement fixation buffer
(CFB) pH 7.4 (Oxoid Ltd, London S.E.1).
In this form antigens were generally
found to be free of anticomplementary
activity. Where necessary they were stored
in liquid nitrogen until required.
Complementfixation (CF) test-.The micro-
complement fixation test used in this study
was essentially that of Sever (1962) as
modified by Hartley etal. (1965). A standard
" microtitre " system was employed (Flow
Laboratories Ltd, Irvine, Scotland) utilizing
96 well leucite plates of capacity 04125 ml.
Diluting loops and pipettes delivered a unit
volume of 0-025 ml of reagent.
Test plates were incubated for 18 hours
at 4°C before the addition of the haemolytic
system and all dilutions were performed in
proprietary CFB.
Pooled whole guinea-pig serum, obtained
by cardiac puncture of a minimum of 3
adult female Hartley strain guinea-pigs, was
stored overnight at 4°C to allow clot
contraction. Exuded serum was spun at
1000 g for 5 min to remove residual red cell
contamination, lyophilized in 1 ml batches
and stored at - 20°C until required. Sera
which appeared discoloured by haemoglobin
were discarded. The complement titre of
the guinea-pig serum was estimated by
titrating in the presence of 0-075 ml CFB
and the end dilution, giving 5000 haemolysis,
considered as 1 minimum haemolytic dose
(MHD). Subsequent complement fixation
tests were performed with 2MHD of comple-
ment in a standard volume of 0-025 ml
CFB.
The haemolytic system consisted of
0 05 ml of a prewarmed mixture of equal
volumes of 1% sheep red blood cells (Mercia
Diagnostics Ltd, Watford, Herts.) in CFB
and rabbit anti-sheep haemolytic serum
(Wellcome Reagents Ltd, Beckenham, Kent)
diluted in buffer to 1: 1000.
After the addition of the indicator
system, plates were sealed with adhesive
tape and incubated at 37°C for 1 hour with
occasional gentle shaking. The complement
fixing titre was recorded as the reciprocal of
the end four-fold dilution giving 5000
haemolysis following centrifugation of plates
at 100 g to facilitate end-point determination.
Where a trace of complement consumption
was observed in the first well which was not
consistent with a reading of 5000 haemolysis,
the titre was recorded as " < 4" and com-
plete visual absence of complement
consumptioni as " 0 ".
Both antigen preparations and serum
samples were tested at a dilution in which
neither was anticomplementary when titrated
in the presence of 2 MHD of complement
under normal test conditions.
RESULTS
Presence of group-specific (gs) antigen in
MSV induced sarcomata and Gross virus
induced lymphomata. Detection by com-
plement fixation with rat antisera
In these tests, antigen preparations
from FBJ sarcomata in CBA mice and
various Gross positive tissues in AS rats
and AKR mice were serially titrated
against a standard dilution (1: 20) of the
test antisera and normal AS rat serum
and the results expressed as reciprocal
CF antigen titres. Antisera originating
from Wistar rats bearing AKR-virus
induced lymphomata, and from AS rats
bearing transplants of lymphomata in-D. B. JONES AND M. MOORE
duced by GLV, were reactive in comple-
ment fixation tests utilizing antigen de-
rived from early generation transplants
of seven independently induced FBJ
sarcomata. Reciprocal titres varied from
8 to 32 and were always one dilution
greater for the AKR rat serum than the
GLV rat serum (Table I). By contrast,
normal rat serum was generally unreactive
under these test conditions, reciprocal
titres being generally zero or occasionally
4.
TABLE I.-Reactivity by Complement Fixa-
tion (CF) of Heterologous Antisera from
Gross Lymphoma Bearing Rats against
Antigens ofOncornavirus Induced Mouse
and Rat Neoplasms
Reciprocal CF antigen titre versus
Source of antigen Rat AKR Rat GLV
(tissue and lymphoma lymphoma Normal
transplant anti- anti- AS rat
generation) serumt serumt serumt
FBJ 4/10 16 16 0
FBJ 7/4 32 16 4
FBJ- 11/4 16 8 0
FBJ 11/5 8 8 0
FBJ 16/7 8 8 0
FBJ 17/6 32 16 4
FBJ 18/2 8 8 0
FBJ 20/9 16 8 0
ASL-1/3 16 8 0
ASL-3/4 8 8 0
AKR-1P 16 16 0
AKR-2P 8 4 0
CH 1* 16 16 0
CH 2* 16 16 0
S15/30 4 4 4
S115/27 0 4 0
Normal CBA 0 0 0
spleen
Normal CBA 0 0 0
muscle
* Tissue cultures of MSV-H sarcoma.
t Serum dilution 1: 20.
P Primary lymphoma.
In addition to antigens prepared from
FBJ sarcomata, these antisera were reac-
tive with antigens prepared from two
transplanted lymphomata induced by
GLV in AS rats (ASL-1 and ASL-3) with
reciprocal titres 8-16, and 2 primary
lymphomata arising spontaneously in
AKR mice, with reciprocal titres of
4-16. Comparable CF reactivity with
these antisera (reciprocal antigen titres,
16) was obtained against antigens pre-
pared from Gross-negative tissues, viz.
early passage cultures of sarcomata in-
duced by MSV-H, a member of the
FMR subgroup ofoncornavirus specificity.
CF antigen titres obtained when the
antisera were tested against normal tissues
(CBA muscle, skin and spleen) and
against 2 radiation-induced transplanted
osteosarcomata (S15, S115) in CBA mice,
of putatively non-viral origin, did not
differ significantly from those obtained
with normal rat serum.
Presence of type-specific antigens in MSV
induced sarcomata and Gross virus infected
tissues. Detection by complement fixation
with mouse antisera
In addition to the demonstration
of antibodies in heterologous sera from
rats bearing MLV induced lymphomata,
CF antibodies were also detected in the
sera of mice exposed to FBJ sarcomata
against antigens present in extracts of
both tumour and spleen.
In the first series, 12 sera from mice
which had received 2 irradiated isografts
of FBJ tumour transplants were tested
against antigen preparations derived from
6 different FBJ sarcomata and the
reactivity compared with sera from 6
normal CBA(H) or CBAT6T6 mice. CF
antibodies were demonstrated in the sera
of all mice exposed to irradiated FBJ
tumour transplants, the reciproqal anti-
body titres ranging from 4-64 (mean
titre 18) compared with 0-4 (mean titre
< 3.3) for sera from normal mice (Table
II).
Similar results were obtained when
5 sera from mice which received irradiated
FBJ sarcoma isografts and 3 normal sera
were tested against spleen homogenates
prepared from 4 mice bearing primary
FBJ sarcomata (Table III). Here CF
antibody titres fell in the range 8-32
(mean titre 12.8) compared with normal
serum titres of 0-4 (mean titre < 2.5).
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TABLE II.-Reactivity by ComplementFixa-
tion (CF) of Homologous Antisera from
FBJ Immune Mice against Antigens
Extractedfrom Transplanted FBJ Sarco-
mata
Source of
immune
Antigen serum*
(tumour and transplant
generation)
FBJ 1/1 FBJ 1/6
FBJ 3/1 FBJ 3/1
FBJ 5/1
FBJ 7/1
FBJ 4/1 FBJ 1/1
FBJ 4/1
FBJ 5/1
FBJ 5/3 FBJ 2/1
FBJ 3/1
FBJ 5/3
FBJ 6/3 FBJ 6/1
FBJ 6/2
FBJ 7/4 FBJ 7/2
Reciprocal CF antibody
titre of
Immune Normal CBA
serum mouse serum
16 <4t
8
8 <4t
8
16
4
8
64
16
64
16
8
8
Source of
Splenic Immune
antigen serum
(tumour and fransplant
generation)
FBJ 1/P FBJ 1/2
FBJ 3/P FBJ 3/1
FBJ 4/P FBJ 4/1
FBJ 6/P FBJ 6/2
FBJ 1/P FBJ 6/2
FBJ 3/P FBJ 5/1
FBJ 4/P FBJ 5/1
FBJ 4/P FBJ 6/2
FBJ 6/P FBJ 7/1
FBJ 6/P FBJ 1/2
Reciprocal CF antibody
titre of
Immune Normal CBA
serum mouse serum
16 <4*
16
8 0
8 <4*
8 <4*
8
8
32
16
8
0
0
<4*
<4*
P Primary FBJ sarcoma bearing CBA mouse.
* <4 denotes trace of complement consumption
in first well.
received irradiated isografts. This was
established in tests in which the reactivity
of sera from 8 tumour bearing donors
against antigens prepared from 4 FBJ
tumour transplants was compared with
that of sera from 4 normal CBA(H) or
CBAT6T6 donors. CF antibody in the
former sera was not invariably detected,
titres falling in the range 0-8 (mean
titre 4.5) compared with 0-4 (mean titre
< 1.3) for sera from control mice (Table
IV). In tests analogous to those under-
taken with heterologous sera, the CF
0
TABLE IV.-Reactivity by CF of Homo-
<4t logous Antisera from FBJ Tumour
Bearers against Antigens Prepared from
_±A 4~ Transplanted FBJ Sarcomata
<4T
<4t Source of
Immune
Antigen serum
(tumour and transplant
generation)
FBJ 1/1 FBJ 6/1
FBJ 8/1
FBJ 5/2 FBJ 3/3
FBJ 5/2
FBJ 6/3 FBJ 7/2
FBJ 7/4
FBJ 7/4 FBJ 12P
FBJ 14P
Reciprocal CF antibody
titre of
Immune Normal CBA
serum mouse serum
4
4
8
8
4
4
0
4
0
0
<4*
0
P Primary FBJ sarcoma bearing CBA mouse.
* <4 denotes trace of complement consumption
in first well.
activity of sera from mice exposed to
FBJ sarcoma was further tested against
various Gross positive tissues, comprising
thymus and spleen from aleukaemic AKR
mice and 2 leukaemic tissues from R1P
mice, a strain known to carry a latent
leukaemia virus (Jenkins and Upton,
1963). Two sera from mice immunized
with FBJ sarcomata (FBJ 7/4 and
FBJ 6/5) were consistently reactive with
antigens prepared from non-loukaemic
AKR and FBJ sarcoma tissues with CF
antibody titres in the range 4-16. Leuk-
aemic tissue from RF/H1 mice reacted
to a higher reciprocal dilution (16-32)
of CF antibody than the other tissues,
while antigen derived from a spontaneous
* CBA mice received 2 irradiated (15,000 rad)
isografts at 14-day intervals. They were bled 10
days after the second immunization.
t <4 denotes trace of complement consumption
in first well.
The titres of CF antibody against
sarcoma derived antigens were signifi-
cantly lower in mice bearing FBJ tumour
transplants than in mice which had
TABLE III.-Reactivity by Complement
Fixation of Homologous Antisera from
FBJ Immune Mice against Antigens
Extracted from the Spleens of Mice
Bearing Primary FBJ SarcomataD. B. JONES AND M. MOORE
A strain murine leukaemia (AF) gave,
with these sera, a result indistinguishable
from that of normal mouse serum (Table
V).
ever, common gs antigens of these sarco-
mata and a GLV-induced rat lymphoma
(ASL-4) were demonstrated, as reported
above, with heterologous antiserum from
rats bearing GLV-induced lymphomata.
TABLE V.-Reactivity by CF of Homo-
logous Antiserafrom FBJ Immune Mice
against Antigens Prepared from Murine
Lymphoid Tissues and Leukaemias
Reciprocal CF
antibody titre of
AA
Source of
Immune
Antigen serum
AKR spleen FBJ 6/5
FBJ 7/4
AKR thymus FBJ 6/5
FBJ 7/4
RF/HI leukaemia FBJ 6/5
FBJ 7/4
RF/OR leukaemia FBJ 6/5
FBJ 7/4
AF-leukaemia FBJ 6/5
FBJ 7/4
FBJ 6/4 FBJ 6/5
FBJ 7/4
Normal
CBA
Immune mouse
serum serum
8
8
4
8
16
32
4
8
0
<4*
8
16
0
<4*
<4*
0
0
0
* <4 denotes trace of complement consumption
in first well.
Evidence was obtained that CF anti-
gens shared by AKR lymphoid tissues
and FBJ sarcomata were not detected
in sarcomata induced by MSV-H. In
these specificity tests sera from FBJ
immune mice were reacted with antigen
extracted from MSV-H tumours; and
sera from mice which had received a
single intraperitoneal injection of MSV-H
were reacted with antigen prepared from
FBJ sarcomata. In neither of these
combinations was significant CF antibody
detected (reciprocal titres < 4) although
sera from FBJ-immune and MSV-H
immune mice reacted positively with the
corresponding sarcoma derived antigens
to reciprocal titres of 16 (Table VI).
Both sera failed to fix complement in
the presence of extracts of normal CBA
spleen and muscle. These data indicate
lack of shared antigen between FBJ
and MSV-H murine sarcomata. How-
TABLE VI. Lack of Shared Antigenic
Type Specificities between Sarcomata
Induced by MSV-FBJ and MSV-H
Demonstrable by CF using Homologous
Antisera to MSV-FBJ and MSV-H
Source of
A
Antigen
FBJ 14/3
FBJ 14/3
CH 3/9
CH 3/9
CH 2/5
CBA
spleen
CBA
spleen
CBA
muscle
CBA
muscle
FBJ 11/6
FBJ 13/4
CH 2/5
CH 3/9
Immune serum
Mouse anti-FBJ
11/4
Mouse anti-MSV-H
Mouse anti-MSV-H
Mouse anti-FBJ
11/4
Mouse anti-MSV-H
Mouse anti-FBJ
11/4
Mouse anti-MSV-H
Mouse anti-FBJ
11/4
MIouse anti-MSV-H
Rat anti-GLV
Rat anti-GLV
Rat anti-GLV
Rat anti-GLV
Reciprocal CF
antibody titre of
Normal
mouse/
Immune rat
serum serum
16 <4*
<4* <4*
16 <4*
<4* <4*
16 <4*
<4* <4*
0 <4*
o o
o 0
16 0
32 0
32 0
16 0
CH, sarcomata induced by MSV-H in CBA
mice.
* <4 denotes trace of complement consumption
in first well.
Presence of complement fixing antigen in
FBJ sarcoma cells reactive with naturally
occurring murine antibody with Gross
(G) specificity
A naturally occurring antibody in the
serum of aged ex-breeding female C57B1
mice was also demonstrated by comple-
ment fixation tests. This antibody was
found to react with antigens prepared
from normal AKR spleen, GLV-induced
rat lymphoma (ASL-4) and FBJ sarco-
mata (FBJ 11/6, 13/4 and 14/3) with
reciprocal titres in the range 16-32 and
were invariably reactive to one dilution
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TABLE VII.-Reactivity of Naturally Occurring CF Antibody in the Serum of Aged
Ex-breeding C57B116 Females with Antigens ofMurine Lymphoid Tissues and MSV-
induced Tumours
Source of
Antigen
AKR-spleen
AKR-spleen
AKR-spleen
ASL-4 primary
ASL-4 primary
FBJ 11/6
FBJ 13/4
FBJ 14/3
CH 2/5
CH 3/9
CBA spleen
CBA muscle
Immune serum
Mouse anti-FBJ 7/6
Aged C57B1 mouse antiserum
Young C57B1 mouse serum
Mouse anti-FBJ 11/4
Aged C57B1 mouse antiserum
Aged C57B1 mouse antiserum
Aged C57B1 mouse antiserum
Aged C57B1 mouse antiserum
Aged C57B1 mouse antiserum
Aged C57B1 mouse antiserum
Aged C57B1 mouse antiserum
Aged C57B1 mouse antiserum
Reciprocal CF antibody titre of
, ~~~A
Immune Normal mouse
serum serum
8
32
4
8
16
16
16
32
4
4
4
<4*
0
0
0
0
0
0
0
<4*
<4*
<4*
<4*
0
CH = sarcomata induced by MSV-H in CBA mice.
* <4 denotes trace of complement consumption in first well.
greater than hyperimmune FBJ antisera
(Table VII). By contrast, the antibody
failed to fix complement in the presence
of similar preparations from MSV-H
induced sarcomata or normal CBA spleen
and muscle, reciprocal titres falling in
the range 0-4. Furthermore, sera from
virgin C57B1 mice less than 10 months
old were unreactive in this test system.
This antibody thus displayed preferential
reactivity with Gross-positive tissues, as
distinct from FMR virus infected tissues
and demonstrated common antigens on
AKR lymphoid and FBJ sarcomatous
tissues.
DISCUSSION
Murine C-type RNA tumour viruses
specify a complex of virion and cellular
antigens. These have been the subject
ofintensive study, particularly in relation
to the antigens of Gross (G) or " wild "
type murine leukaemia virus (MLV).
Classification of various specificities has
been made possible by the production of
anti-sera inl heterologous and homologous
hosts and the use of naturally occurring
antibodies in certain strains (e.g. C57B1)
highly resistant to MLV' oncogenesis
(Aoki et al., 1972). To examine the'
relationship of the FBJ viruses to Gross
or " wild " type leukaemias and to
another MSV isolate, MSV-H, we have
used rat and mouse antisera with CF
activity to antigens specified by viruses
of the MLV-MSV complex.
'An antigen common to murine C-type
RNA tumour viruses has been demon-
strated by various serological techniques,
including immunodiffusion (Geering, Old
and Boyse, 1966) complement fixation
(Hartley et al., 1965) and immuno-
fluorescence (Lejneva and Abelev, 1970)
and has been shown to be an internal
component of the virus particle (Schafer
et al., 1969). For the detection of this
antigen, termed the species or group
specific (gs) antigen (Gilden and Oroszlan,
1971), sera were raised in heterologous
hosts bearing neoplasms induced by the
murine agents or by immunization with
disrupted virus particles. The' former
method evokes a complex humoral re-
sponse involving antibodies to several
antigenic specificities including gs and
virion envelope antigens (VEA) (Herber-
man, 1972) as well as cell surface com-
ponents, such as Gross cell surface antigens
(GCSA), and type specific non-virion anti-
gens determined by the viral genome on
the surface of Gross virus infected cells
(Stockert, Old and Boyse, 1971).
In this study, all tumours inducedD. B. JONES AND M. MOORE
by MSV-FBJ were positive in the CF
test using seraraised in our own laboratory
from AS rats bearing transplants of
GLV induced lymphomata and with
reference AKR rat antisera obtained
from the National Institutes of Health,
U.S.A. Similar CF reactivity was ob-
served against antigen prep4red from
cells transformed by the FMR subgroup
sarcoma virus (MSV-H), from primary
AKR mouse lymphomata and from the
immunizing GLV-induced lymphoma.
These antisera raised against Gross and
AKR viruses undoubtedly contain anti-
bodies to VEA of the G subgroup as
well as other specificities since they
effectively neutralize virus and react with
membrane expressed VEA, as assessed
by indirect IF tests (to be published).
However, the spectrum of CF activity
with the rat antisera indicates that the
shared specificity ofGand FMR neoplasms
is predominantly that of the gs antigen
of the murine leukaemia-sarcoma virus
complex. Confirmation of this conclu-
sion has come from immunofluorescence
studies on the localization of gs antigen
in acetone fixed monolayers of cells
transformed in vivo by MSV-FBJ and
MSV-H (unpublished data). No attempt
was made in this study to distinguish
between the various subgroup specific
antigens (gs 1, 3).
Immunization of homologous hosts
withMLV-MSV antigens evokes ahumoral
response to a different though related
antigenic spectrum. Since mice are com-
pletely tolerant to the gs antigen, anti-
bodies to the internal component of the
virus are not produced. Antibodies may,
however, be produced to VEA and
GCSA as well as to alloantigenic specifici-
ties. In this study, the evocation of
alloantibodies was precluded by the use
ofstrictly syngeneic recipients for immun-
ization against FBJ transformed cells.
Sera raised by this protocol permitted
distinction between virus induced neo-
plasms expressing antigens of different
type specificities.
All FBJ tumours were positive in the
CF test with sera from mice which had
received irradiated isografts of FBJ sarco-
mata. CF antigen was also detected in
extracts of the spleens of mice bearing
primary FBJ induced sarcomata. CF
antibody titres were lowest, and-occasion-
ally indetectable, in mice bearing tumour
transplants, which is suggestive of the
formation ofantigen-antibody complexes.
Whether the antibodies detected with the
homologous sera are to VEA or GCSA,
or both antigens, was not resolved in this
study. Sera from FBJ tumour bearers
are virus neutralizing (Kelloff et al.,
1969) which is indicative of anti-VEA
antibodies. The coexistence of anti-
bodies with specificity for GCSA cannot,
however, be excluded. Studies under-
taken in parallel by membrane immuno-
fluorescence have shown that the anti-
bodies evoked are essentially to membrane
expressed antigens (to be published).
Consistent with the interpretation that
hyperimmune FBJ sera contain anti-
VEA antibodies (and probably anti-
GCSA antibodies), antigens extractedfrom
normal AKR lymphoid tissues in which
Gross leukaemia virus is indigenous, were
active in the CF test. Of additional
interest was the expression of this CF
antigen in a radiogenic myeloid leukaemia
of RF mice, transmissible in cell-free
extracts and therefore putatively of viral
aetiology. Positive reactivity with sera
exhibiting specificity for Gross virus
related antigens suggests that the putative
agent is also of " wild " type subgroup,
although antigenic conversion of this
long transplanted line' is a possibility
which cannot be excluded. By contrast,
CF tests undertaken with extracts from
a spontaneous A strain leukaemia, for
which a viral aetiology has not been
established (Marchant, personal communi-
cation) were negative.
Further specificity tests with antigens
prepared from primary AKR lymphomata
confirmed the Gross type specificity of
the CF antigen reactive withhyperimmune
FBJ sera. By contrast, antigenic dis-
tinction from MSV-H was established in
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reciprocal CF tests with antisera prepared
in the respectively immunized donors
and antigens from the corresponding
tumour tissues. MSV-H is antigenically
indistinguishable from other leukaemic
and sarcomagenic agents of the FMR
subgroup, as demonstrated by trans-
plantation tests, serological techniques
and in vitro cell mediated cytotoxicity
(Chuat et al., 1969). The lack of antigen
cross reactivity by CF emphasizes the
separate categories of the MSV isolates,
MSV-FBJ and MSV-H, and the unique-
ness of the former as the only known
"wild " type sarcomagenic virus.
Further data on the Gross type
specificity of FBJ sarcoma cells and the
nature of antigens expressed by them
were derived from CF tests undertaken
with sera from aged exbreeding C57B1
female mice which have been shown to
develop antibody of G specificity (Aoki
et al., 1966) but without demonstrable
virus neutralizing activity. Immunoelec-
tron microscopic studies (Aoki et al.,
1970) confirmed that the antigen de-
tected by the naturally occurring G
antibody was a cellular antigen and not
a constituent of the virion. In the
present study, reactivity of C57B1 anti-
sera closely paralleled that of hyper-
immune FBJ sera, indicating that cellular
and virion specificities are simultaneously
present in FBJ sarcoma cells. Moreover,
the reactivity of the C57B1 antibody by
CF was comparable with that detected
in the same sera by membrane immuno-
fluorescence on AKR lymphoid and FBJ
sarcoma cells, suggesting that the anti-
bodies detected by the two methods may
be identical. It is possible that CF
antigen represents exfoliated GCSA.
Equally tenable, however, are the alterna-
tives that the CF antibody present in
C57B1 antiserum reacts with G soluble
antigen (GSA) sharing a common specifi-
city with GCSA (Aoki et al., 1972), or
that these antisera contain G antibodies
of more than one specificity.
Whilst there are likely to be other
virus associated antigens present on cells
replicating FBJ viruses, these data con-
firm the Gross-type specificity of FBJ
sarcomata and indicate the presence of G
type-specific cellular (GCSA) and virion
antigens (VEA) in cells transformed
by this agent.
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